3.96
price down icon5.26%   -0.22
after-market アフターアワーズ: 3.95 -0.010 -0.25%
loading
前日終値:
$4.18
開ける:
$4.18
24時間の取引高:
348.79K
Relative Volume:
0.43
時価総額:
$213.60M
収益:
$2.81M
当期純損益:
$-97.34M
株価収益率:
-2.5063
EPS:
-1.58
ネットキャッシュフロー:
$-91.47M
1週間 パフォーマンス:
-4.81%
1か月 パフォーマンス:
-15.74%
6か月 パフォーマンス:
-57.33%
1年 パフォーマンス:
-45.15%
1日の値動き範囲:
Value
$3.93
$4.24
1週間の範囲:
Value
$3.86
$4.325
52週間の値動き範囲:
Value
$2.86
$13.70

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
名前
Fulcrum Therapeutics Inc
Name
セクター
Healthcare (1173)
Name
電話
617-651-8851
Name
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
職員
89
Name
Twitter
@fulcrumtx
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
FULC's Discussions on Twitter

FULC を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FULC
Fulcrum Therapeutics Inc
3.96 213.60M 2.81M -97.34M -91.47M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
461.68 118.90B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.98 73.95B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
655.13 39.81B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
271.31 34.99B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
123.77 29.67B 3.30B -501.07M 1.03B -2.1146

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-09-13 ダウングレード H.C. Wainwright Buy → Neutral
2024-09-12 ダウングレード BofA Securities Neutral → Underperform
2024-09-12 ダウングレード Cantor Fitzgerald Overweight → Neutral
2024-09-12 ダウングレード Leerink Partners Outperform → Market Perform
2024-09-12 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2024-09-12 ダウングレード Stifel Buy → Hold
2024-09-09 アップグレード BofA Securities Underperform → Neutral
2024-05-20 開始されました Cantor Fitzgerald Overweight
2024-03-13 開始されました RBC Capital Mkts Outperform
2023-09-25 開始されました Goldman Neutral
2023-08-23 アップグレード H.C. Wainwright Neutral → Buy
2023-08-22 アップグレード Stifel Hold → Buy
2023-05-04 ダウングレード Goldman Buy → Neutral
2023-03-10 ダウングレード Credit Suisse Outperform → Neutral
2023-03-10 ダウングレード H.C. Wainwright Buy → Neutral
2023-03-09 ダウングレード Stifel Buy → Hold
2023-02-28 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-02-24 ダウングレード BofA Securities Neutral → Underperform
2022-11-15 開始されました Goldman Buy
2022-03-08 開始されました Oppenheimer Outperform
2022-03-03 アップグレード BofA Securities Underperform → Neutral
2021-08-11 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-04-26 再開されました Credit Suisse Outperform
2021-03-22 開始されました Credit Suisse Outperform
2021-03-02 開始されました Stifel Buy
2020-10-16 開始されました Piper Sandler Overweight
2020-08-12 ダウングレード BofA Securities Neutral → Underperform
2020-08-12 繰り返されました H.C. Wainwright Buy
2020-08-12 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-06-19 ダウングレード BofA/Merrill Buy → Neutral
2020-06-17 開始されました BTIG Research Buy
2019-10-03 開始されました H.C. Wainwright Buy
2019-08-12 開始されました BofA/Merrill Buy
すべてを表示

Fulcrum Therapeutics Inc (FULC) 最新ニュース

pulisher
Jan 28, 2025

Fulcrum Therapeutics (NASDAQ:FULC) versus Syros Pharmaceuticals (NASDAQ:SYRS) Financial Analysis - Defense World

Jan 28, 2025
pulisher
Jan 19, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Barclays PLC - Defense World

Jan 19, 2025
pulisher
Jan 19, 2025

Barclays PLC Acquires 97,565 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Jan 19, 2025
pulisher
Jan 13, 2025

Fulcrum Therapeutics Advances Pociredir for Sickle Cell Disease - TipRanks

Jan 13, 2025
pulisher
Jan 12, 2025

Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - Defense World

Jan 12, 2025
pulisher
Jan 09, 2025

Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - MarketBeat

Jan 09, 2025
pulisher
Jan 06, 2025

Suvretta Capital Management, LLC Acquires Additional Shares in F - GuruFocus.com

Jan 06, 2025
pulisher
Jan 06, 2025

Geode Capital Management LLC Raises Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Jan 06, 2025
pulisher
Jan 04, 2025

Barclays PLC Boosts Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Jan 04, 2025
pulisher
Dec 31, 2024

Stifel Financial Corp Decreases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Dec 31, 2024
pulisher
Dec 30, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat

Dec 30, 2024
pulisher
Dec 29, 2024

State Street Corp Increases Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 29, 2024
pulisher
Dec 29, 2024

State Street Corp Boosts Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Dec 29, 2024
pulisher
Dec 27, 2024

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online

Dec 27, 2024
pulisher
Dec 24, 2024

Fulcrum Therapeutics jumps amid takeover speculation - MSN

Dec 24, 2024
pulisher
Dec 24, 2024

Fulcrum Therapeutics Receives Termination Notice from Sanofi Ending Collaboration Agreement for Losmapimod - Defense World

Dec 24, 2024
pulisher
Dec 23, 2024

There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump - Simply Wall St

Dec 23, 2024
pulisher
Dec 22, 2024

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from S&P Pharmaceuticals Select Industry Index - Marketscreener.com

Dec 22, 2024
pulisher
Dec 19, 2024

Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago - Yahoo Finance

Dec 19, 2024
pulisher
Dec 18, 2024

Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World

Dec 18, 2024
pulisher
Dec 17, 2024

Charles Schwab Investment Management Inc. Acquires 393,202 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

Charles Schwab Investment Management Inc. Has $2.03 Million Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Dec 17, 2024
pulisher
Dec 16, 2024

Fulcrum Therapeutics' SWOT analysis: stock faces headwinds after trial setback - Investing.com

Dec 16, 2024
pulisher
Dec 15, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Dec 15, 2024
pulisher
Dec 13, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Holdings Trimmed by Fmr LLC - MarketBeat

Dec 13, 2024
pulisher
Dec 13, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Fmr LLC - Defense World

Dec 13, 2024
pulisher
Dec 12, 2024

Fulcrum Therapeutics Insider Purchases Yet To Pay Off Regardless Of Recent Strength - Simply Wall St

Dec 12, 2024
pulisher
Dec 10, 2024

Jacobs Levy Equity Management Inc. Takes $721,000 Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 10, 2024
pulisher
Dec 07, 2024

BlackRock, Inc. Reduces Stake in Fulcrum Therapeutics Inc. - GuruFocus.com

Dec 07, 2024
pulisher
Dec 05, 2024

Fulcrum Therapeutics' SWOT analysis: stock faces challenges after trial setback - Investing.com Nigeria

Dec 05, 2024
pulisher
Dec 05, 2024

RA Capital Management L.P. Sells 1,380,605 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 05, 2024
pulisher
Nov 30, 2024

Braidwell LP Acquires New Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 30, 2024
pulisher
Nov 30, 2024

Connor Clark & Lunn Investment Management Ltd. Makes New $474,000 Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 30, 2024
pulisher
Nov 29, 2024

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why - MSN

Nov 29, 2024
pulisher
Nov 29, 2024

Suvretta Capital Management LLC Sells 1,358,255 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 29, 2024
pulisher
Nov 27, 2024

Fulcrum Therapeutics to Participate in Upcoming December Conferences - The Manila Times

Nov 27, 2024
pulisher
Nov 26, 2024

Fulcrum Therapeutics to Present at Three Major Healthcare Conferences in December | FULC Stock News - StockTitan

Nov 26, 2024
pulisher
Nov 21, 2024

CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz

Nov 21, 2024
pulisher
Nov 19, 2024

Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche - The Globe and Mail

Nov 19, 2024

Fulcrum Therapeutics Inc (FULC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$39.42
price down icon 3.95%
$351.17
price down icon 0.32%
$21.50
price down icon 3.85%
$5.30
price down icon 2.03%
biotechnology ONC
$224.99
price down icon 0.84%
$123.77
price up icon 2.39%
大文字化:     |  ボリューム (24 時間):